Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies

Electrolyte and Blood Pressure

Volumn 12, Issue 2, 2014, Pages 55-65

  Oh, Gi Su ^a   Kim, Hyung Jin ^a   Shen, AiHua ^a   Lee, Su Bin ^a   Khadka, Dipendra ^a   Pandit, Arpana ^a   So, Hong Seob ^a  

^a Wonkwang University School of Medicine   (South Korea)

Author keywords

Chemotherapy; Cisplatin; NAD+; Nephrotoxicity

Indexed keywords

CISPLATIN; DIURETIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA DAMAGE; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; NEPHROTOXICITY; OXIDATIVE STRESS; RENAL PROTECTION;

EID: 84921688340     PISSN: 17385997     EISSN: 20929935     Source Type: Journal    
DOI: 10.5049/EBP.2014.12.2.55     Document Type: Article

References (85)

1. Yao X, Panichpisal K, Kurtzman N and Nugent K: Cisplatin nephrotoxicity: a review. The American journal of the medical sciences 334:115-24, 2007
2. Sastry J and Kellie SJ: Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatric hematology and oncology 22:441-5, 2005
3. Miller RP, Tadagavadi RK, Ramesh G and Reeves WB: Mechanisms of Cisplatin nephrotoxicity. Toxins 2:2490-518, 2010
4. Ciarimboli G: Membrane transporters as mediators of cisplatin side-effects. Anticancer research 34:547-50, 2014
5. Ciarimboli G: Organic cation transporters. Xenobiotica; the fate of foreign compounds in biological systems 38: 936-71, 2008
6. Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, Hashimoto Y and Inui K: Gender differences in expre-ssion of organic cation transporter OCT2 in rat kidney. FEBS letters 461:339-42, 1999
7. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstadt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jurgens H and Schlatter E: Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. The American journal of pathology 176:1169-80, 2010
8. Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH and Sparreboom A: Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res 16:4198-206, 2010
9. Pabla N, Murphy RF, Liu K and Dong Z: The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. American journal of physiology. Renal physiology 296:F505-11, 2009
10. Townsend DM, Tew KD, He L, King JB and Hanigan MH: Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomedicine & pharmacotherapy =Biomedecine & pharmacotherapie 63:79-85, 2009
11. Hanigan MH, Lykissa ED, Townsend DM, Ou CN, Barrios R and Lieberman MW: Gamma-glutamyl trans-peptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. The American journal of pathology 159:1889-94, 2001
12. Hanigan MH, Gallagher BC, Townsend DM and Gabarra V: Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 20:553-9, 1999
13. Townsend DM, Deng M, Zhang L, Lapus MG and Hanigan MH: Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. Journal of the American Society of Nephrology: JASN 14:1-10, 2003
14. Zhang L and Hanigan MH: Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. The Journal of pharmacology and experimental therapeutics 306: 988-94, 2003
15. Kuhlmann MK, Burkhardt G and Kohler H: Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 12:2478-80, 1997
16. Pabla N and Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney international 73:994-1007, 2008
17. Jiang M and Dong Z: Regulation and pathological role of p53 in cisplatin nephrotoxicity. The Journal of pharmacology and experimental therapeutics 327:300-7, 2008
18. Lee RH, Song JM, Park MY, Kang SK, Kim YK and Jung JS: Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochemical pharmacology 62:1013-23, 2001
19. Ramesh G and Reeves WB: Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-alpha. Kidney international 65:490-9, 2004
20. Strasser A, O'Connor L and Dixit VM: Apoptosis signa-ling. Annual review of biochemistry 69:217-45, 2000
21. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H and Iida M: Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney international 63: 72-82, 2003
22. Seth R, Yang C, Kaushal V, Shah SV and Kaushal GP: p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. The Journal of biological chemistry 280:31230-9, 2005
23. Takeda M, Kobayashi M, Shirato I, Osaki T and Endou H: Cisplatin-induced apoptosis of immortalized mouse proximal tubule cells is mediated by interleukin-1 beta converting enzyme (ICE) family of proteases but inhibited by overexpression of Bcl-2. Archives of toxicology 71: 612-21, 1997
24. Park MS, De Leon M and Devarajan P: Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. Journal of the American Society of Nephrology: JASN 13:858-65, 2002
25. Peyrou M, Hanna PE and Cribb AE: Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicological sciences : an official journal of the Society of Toxicology 99:346-53, 2007
26. Price PM, Safirstein RL and Megyesi J: Protection of renal cells from cisplatin toxicity by cell cycle inhibitors. American journal of physiology. Renal physiology 286: F378-84, 2004
27. Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL and Megyesi J: Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. Journal of the American Society of Nephrology: JASN 17:2434-42, 2006
28. Bassett EA, Wang W, Rastinejad F and El-Deiry WS: Structural and functional basis for therapeutic modulation of p53 signaling. Clinical cancer research: an official journal of the American Association for Cancer Research 14:6376-86, 2008
29. Wei Q, Dong G, Yang T, Megyesi J, Price PM and Dong Z: Activation and involvement of p53 in cisplatin-induced nephrotoxicity. American journal of physiology. Renal physiology 293:F1282-91, 2007
30. Molitoris BA, Dagher PC, Sandoval RM, Campos SB, Ashush H, Fridman E, Brafman A, Faerman A, Atkinson SJ, Thompson JD, Kalinski H, Skaliter R, Erlich S and Feinstein E: siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. Journal of the American Society of Nephrology: JASN 20:1754-64, 2009
31. Clark JS, Faisal A, Baliga R, Nagamine Y and Arany I: Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells. Cancer letters 297:165-70, 2010
32. Dickey DT, Wu YJ, Muldoon LL and Neuwelt EA: Pro-tection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. The Journal of pharmacology and experimental therapeutics 314:1052-8, 2005
33. Baliga R, Zhang Z, Baliga M, Ueda N and Shah SV: In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney international 53:394-401, 1998
34. Davis CA, Nick HS and Agarwal A: Manganese superoxide dismutase attenuates Cisplatin-induced renal injury: importance of superoxide. Journal of the American Society of Nephrology: JASN 12:2683-90, 2001
35. Ma SF, Nishikawa M, Hyoudou K, Takahashi R, Ikemura M, Kobayashi Y, Yamashita F and Hashida M: Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity. Kidney international 72:1474-82, 2007
36. Naziroglu M, Karaoglu A and Aksoy AO: Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 195:221-30, 2004
37. Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, Nick HS and Agarwal A: Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. American journal of physiology. Renal physiology 278:F726-36, 2000
38. Kawai Y, Nakao T, Kunimura N, Kohda Y and Gemba M: Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. Journal of pharmacological sciences 100:65-72, 2006
39. Yilmaz HR, Iraz M, Sogut S, Ozyurt H, Yildirim Z, Akyol O and Gergerlioglu S: The effects of erdosteine on the activities of some metabolic enzymes during cisplatin-induced nephrotoxicity in rats. Pharmacological research: the official journal of the Italian Pharmacological Society 50:287-90, 2004
40. Badary OA, Abdel-Maksoud S, Ahmed WA and Owieda GH: Naringenin attenuates cisplatin nephrotoxicity in rats. Life sciences 76:2125-35, 2005
41. Chirino YI, Hernandez-Pando R and Pedraza-Chaverri J: Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC pharmacology 4:20, 2004
42. Kelly KJ, Meehan SM, Colvin RB, Williams WW and Bonventre JV: Protection from toxicant-mediated renal injury in the rat with anti-CD54 antibody. Kidney international 56:922-31, 1999
43. Oh GS, Kim HJ, Choi JH, Shen A, Choe SK, Karna A, Lee SH, Jo HJ, Yang SH, Kwak TH, Lee CH, Park R and So HS: Pharmacological activation of NQO1 increases NAD(+) levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney international 85:547-60, 2014
44. Ramesh G and Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. The Journal of clinical investigation 110:835-42, 2002
45. Kim YK, Choi TR, Kwon CH, Kim JH, Woo JS and Jung JS: Beneficial effect of pentoxifylline on cisplatin-induced acute renal failure in rabbits. Renal failure 25:909-22, 2003
46. Zhang B, Ramesh G, Norbury CC and Reeves WB: Cis-platin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 72:37-44, 2007
47. Ramesh G and Reeves WB: p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. American journal of physiology. Renal physiology 289:F166-74, 2005
48. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian bio-logy. Cell 104:487-501, 2001
49. Ramesh G and Reeves WB: TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. American journal of physiology. Renal physiology 285: F610-8, 2003
50. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA and Edelstein CL: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. The Journal of pharmacology and experimental therapeutics 322:8-15, 2007
51. Lu LH, Oh DJ, Dursun B, He Z, Hoke TS, Faubel S and Edelstein CL: Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. The Journal of pharmacology and experi-mental therapeutics 324:111-7, 2008
52. Zhang Y, Yuan F, Cao X, Zhai Z, GangHuang, Du X, Wang Y, Zhang J, Huang Y, Zhao J and Hou W: P2X7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3. Toxicology and applied pharmacology: 2014
53. Cornelison TL and Reed E: Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecologic oncology 50:147-58, 1993
54. Hanigan MH, Deng M, Zhang L, Taylor PT, Jr. and Lapus MG: Stress response inhibits the nephrotoxicity of cisplatin. American journal of physiology. Renal physiology 288:F125-32, 2005
55. Lynch ED, Gu R, Pierce C and Kil J: Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hearing research 201:81-9, 2005
56. Nisar S and Feinfeld DA: N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Renal failure 24:529-33, 2002
57. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S and Star RA: Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney international 60:2118-28, 2001
58. Nagothu KK, Bhatt R, Kaushal GP and Portilla D: Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney international 68:2680-93, 2005
59. Kitada M and Koya D: Renal protective effects of resveratrol. Oxidative medicine and cellular longevity 2013:568093, 2013
60. Catalgol B, Batirel S, Taga Y and Ozer NK: Resveratrol: French paradox revisited. Frontiers in pharmacology 3:141, 2012
61. Valentovic MA, Ball JG, Brown JM, Terneus MV, McQuade E, Van Meter S, Hedrick HM, Roy AA and Williams T: Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress. Toxicology in vitro: an international journal published in association with BIBRA 28:248-57, 2014
62. Kim DH, Jung YJ, Lee JE, Lee AS, Kang KP, Lee S, Park SK, Han MK, Lee SY, Ramkumar KM, Sung MJ and Kim W: SIRT1 activation by resveratrol ameliorates cis-platin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol 301:F427-35, 2011
63. Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM and Bianchi Mde L: Resvera-trol attenuates cisplatin-induced nephrotoxicity in rats. Archives of toxicology 82:363-70, 2008
64. Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K and Koya D: Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clinical science 124: 153-64, 2013
65. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B and Sinclair DA: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-6, 2003
66. Guarente L: Sirtuins, aging, and metabolism. Cold Spring Harbor symposia on quantitative biology 76:81-90, 2011
67. Hwang JH, Kim DW, Jo EJ, Kim YK, Jo YS, Park JH, Yoo SK, Park MK, Kwak TH, Kho YL, Han J, Choi HS, Lee SH, Kim JM, Lee I, Kyung T, Jang C, Chung J, Kweon GR and Shong M: Pharmacological stimulation of NADH oxidation ameliorates obesity and related phenotypes in mice. Diabetes 58:965-74, 2009
68. Kim SY, Jeoung NH, Oh CJ, Choi YK, Lee HJ, Kim HJ, Kim JY, Hwang JH, Tadi S, Yim YH, Lee KU, Park KG, Huh S, Min KN, Jeong KH, Park MG, Kwak TH, Kweon GR, Inukai K, Shong M and Lee IK: Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circulation research 104:842-50, 2009
69. Houtkooper RH, Canto C, Wanders RJ and Auwerx J: The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocrine reviews 31:194-223, 2010
70. Kim YH, Hwang JH, Noh JR, Gang GT, Kim do H, Son HY, Kwak TH, Shong M, Lee IK and Lee CH: Activation of NAD(P)H:quinone oxidoreductase ameliorates spontaneous hypertension in an animal model via modulation of eNOS activity. Cardiovascular research 91:519-27, 2011
71. Lee JS, Park AH, Lee SH, Kim JH, Yang SJ, Yeom YI, Kwak TH, Lee D, Lee SJ, Lee CH, Kim JM and Kim D: Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PloS one 7:e47122, 2012
72. Kim YH, Hwang JH, Noh JR, Gang GT, Tadi S, Yim YH, Jeoung NH, Kwak TH, Lee SH, Kweon GR, Kim JM, Shong M, Lee IK and Lee CH: Prevention of salt-induced renal injury by activation of NAD(P)H:quinone oxidoreductase 1, associated with NADPH oxidase. Free radical biology & medicine 52:880-8, 2012
73. Kim HJ, Oh GS, Shen A, Lee SB, Choe SK, Kwon KB, Lee S, Seo KS, Kwak TH, Park R and So HS: Augmenta-tion of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment. Cell death & disease 5:e1292, 2014
74. Gaikwad A, Long DJ, 2nd, Stringer JL and Jaiswal AK: In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. The Journal of biological chemistry 276:22559-64, 2001
75. Gessner DK, Ringseis R, Siebers M, Keller J, Kloster J, Wen G and Eder K: Inhibition of the pro-inflammatory NF-kappaB pathway by a grape seed and grape marc meal extract in intestinal epithelial cells. Journal of animal physiology and animal nutrition 96:1074-83, 2012
76. Pazdro R and Burgess JR: The antioxidant 3H-1,2-di-thiole- 3-thione potentiates advanced glycation end-prod-uct-induced oxidative stress in SH-SY5Y cells. Experimen-tal diabetes research 2012:137607, 2012
77. Moscovitz O, Tsvetkov P, Hazan N, Michaelevski I, Keisar H, Ben-Nissan G, Shaul Y and Sharon M: A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1. Molecular cell 47:76-86, 2012
78. Pardee AB, Li YZ and Li CJ: Cancer therapy with beta-lapachone. Current cancer drug targets 2:227-42, 2002
79. Imai S and Kiess W: Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Frontiers in bioscience 14:2983-95, 2009
80. Abdellatif M: Sirtuins and pyridine nucleotides. Circulation research 111:642-56, 2012
81. Michan S and Sinclair D: Sirtuins in mammals: insights into their biological function. The Biochemical journal 404:1-13, 2007
82. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M and Guarente L: Mam-malian SIRT1 represses forkhead transcription factors. Cell 116:551-63, 2004
83. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX and Finkel T: A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America 105:14447-52, 2008
84. Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM and Walsh MJ: p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PloS one 5:e10486, 2010
85. Abali H, Urun Y, Oksuzoglu B, Budakoglu B, Yildirim N, Guler T, Ozet G and Zengin N: Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer investigation 26:401-6, 2008